145 related articles for article (PubMed ID: 37714429)
21. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
[TBL] [Abstract][Full Text] [Related]
22. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
23. [Third French multidisciplinary meeting on Fabry disease].
Germain DP
Rev Med Interne; 2010 Dec; 31 Suppl 2():S205-8. PubMed ID: 21211664
[No Abstract] [Full Text] [Related]
24. New therapies for Fabry's disease.
Gahl WA
N Engl J Med; 2001 Jul; 345(1):55-7. PubMed ID: 11439950
[No Abstract] [Full Text] [Related]
25. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
26. [Fabry disease: Pathogenesis, pathophysiology, and therapy].
Utsumi K
Nihon Rinsho; 2006 Feb; 64 Suppl 2():537-40. PubMed ID: 16523950
[No Abstract] [Full Text] [Related]
27. [Fabry disease - complex clinical picture, simple diagnosis procedure, causal treatment].
Hoffmann B; Beck M; Rolfs A; Neumann HP
Dtsch Med Wochenschr; 2008 Sep; 133(39):1965-72; quiz 1973-4. PubMed ID: 18798134
[No Abstract] [Full Text] [Related]
28. A case of latent heterozygous Fabry disease in a female living kidney donor candidate.
Minami M; Mizuma E; Nakahara M; Oda Y; Yoshimine H; Tokunaga K; Mitsuke A; Yamada Y; Enokida H; Masutani K; Goto N; Ido A
CEN Case Rep; 2021 Feb; 10(1):30-34. PubMed ID: 32712909
[TBL] [Abstract][Full Text] [Related]
29. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
30. [Fabry disease. An interdisciplinary challenge].
Cybulla M; Neumann HP
Dtsch Med Wochenschr; 2007 Oct; 132(43):2271-7. PubMed ID: 17940933
[TBL] [Abstract][Full Text] [Related]
31. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
[No Abstract] [Full Text] [Related]
32. A case of minimal change disease in a Fabry patient.
Zarate YA; Patterson L; Yin H; Hopkin RJ
Pediatr Nephrol; 2010 Mar; 25(3):553-6. PubMed ID: 19876652
[TBL] [Abstract][Full Text] [Related]
33. Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM; Simpson D
Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
[TBL] [Abstract][Full Text] [Related]
34. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
35. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.
Najafian B; Silvestroni A; Sokolovskiy A; Tøndel C; Svarstad E; Obrisca B; Ismail G; Holida MD; Mauer M
Kidney Int; 2022 Jul; 102(1):173-182. PubMed ID: 35483528
[TBL] [Abstract][Full Text] [Related]
36. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
37. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
38. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
Demontis R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
[TBL] [Abstract][Full Text] [Related]
39. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
40. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
Roganović J
Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]